Blinded, randomized, and placebo-controlled probiotic treatment of symptomatic outpatient COVID-19 patients has been shown to modulate the immune response, significantly increasing SARS-CoV-2-specific IgM and IgG levels (Gutiérrez-Castrellón et al., 2022). The gene discussed is CD40LG; the disease is COVID-19.